, Remes et al. 2019 ). An emerging class of therapeutics for patients with WD NETs consists of radiolabeled somatostatin analogs (SSA), which fall under the broader therapeutic class of peptide receptor radionuclide therapy (PRRT). PRRT enables the
Search Results
Mintallah Haider, Satya Das, Taymeyah Al-Toubah, Eleonora Pelle, Ghassan El-Haddad, and Jonathan Strosberg
Tessa Brabander, Julie Nonnekens, and Johannes Hofland
prospects to improve peptide receptor radionuclide therapy in patients. Hsp90, heat shock protein 90; mTOR, mammalian target of rapamycin; PARP, poly ADP-ribose polymerase; PD-L1, programmed death ligand-1; SST2, somatostatin receptor type 2
Halfdan Sorbye, Grace Kong, and Simona Grozinsky-Glasberg
Background Peptide receptor radionuclide therapy (PRRT) Peptide receptor radionuclide therapy (PRRT) delivers highly localized radiation by targeting specific peptide receptors on tumor cells ( Hicks et al . 2017 ). This therapy has been
Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom
time of presentation ( Korse et al . 2013 ). In the past decade a promising new treatment modality has been developed for inoperable or metastasized NETs. This peptide receptor radionuclide therapy (PRRT) uses radiolabeled somatostatin analogues. Since
Esben Andreas Carlsen, Nicola Fazio, Dan Granberg, Simona Grozinsky-Glasberg, Hojjat Ahmadzadehfar, Chiara Maria Grana, Wouter T Zandee, Jaroslaw Cwikla, Martin A Walter, Peter Sandor Oturai, Anja Rinke, Andrew Weaver, Andrea Frilling, Sara Gritti, Anne Kirstine Arveschoug, Amichay Meirovitz, Ulrich Knigge, and Halfdan Sorbye
, Yamaguchi et al . 2014 , Heetfeld et al . 2015 , Walter et al . 2017 ). In metastatic GEP NET G1–G2, peptide receptor radionuclide therapy (PRRT) targeting somatostatin receptors has been used with excellent results for the last two decades in Europe
Lisa Bodei, Irvin M Modlin, Markus Luster, Flavio Forrer, Marta Cremonesi, Rodney J Hicks, Samer Ezziddin, Mark Kidd, and Arturo Chiti
Introduction It is now widely accepted that peptide receptor radionuclide therapy (PRRT) is an effective treatment for inoperable or metastatic neuroendocrine tumors (NETs), particularly well-differentiated gastroenteropancreatic (GEP) or
Jaap J M Teunissen, Dik J Kwekkeboom, R Valkema, and Eric P Krenning
patients who had inoperable and/or metastasised NETs. Therefore, the first peptide receptor radionuclide therapy (PRRT) was performed with high administered activity of [ 111 In-DTPA 0 ]octreotide ( Krenning et al . 1994 a ). However, besides encouraging
Cecile N Chougnet, Sophie Leboulleux, Caroline Caramella, Jean Lumbroso, Isabelle Borget, Désirée Déandreis, Pierre Duvillard, Dominique Elias, Thierry de Baere, Fritz-Line Vélayoudom-Céphise, Joël Guigay, Michel Ducreux, Martin Schlumberger, and Eric Baudin
tomography (PET)-dedicated tracers ( Ambrosini et al . 2008 , Srirajaskanthan et al . 2010 ) and the use of tracers with higher affinity for sstr ( Krenning et al . 1999 , Carrasquillo & Chen 2010 ). Peptide receptor radionuclide therapy (PRRT) that uses
Dik J Kwekkeboom, Boen L Kam, Martijn van Essen, Jaap J M Teunissen, Casper H J van Eijck, Roelf Valkema, Marion de Jong, Wouter W de Herder, and Eric P Krenning
, the follow-up of patients with known disease, and lastly the selection of patients with inoperable and/or metastatic tumors for peptide receptor radionuclide therapy (PRRT). Newer ligands for SRI 99m Tc-Depreotide (Neotect, Diatide, Londonderry
David A Pattison and Rodney J Hicks
in patients deemed otherwise suitable for peptide receptor radionuclide therapy (PRRT). Figure 1 Molecular targets currently utilised for imaging and radionuclide therapy of insulinoma. Adapted from Trends in Endocrinology & Metabolism , Vol